NovalGen
Phase 1NovalGen is an innovative immunotherapy company focused on next-generation multi-specific antibody approaches
Founded
2018
Focus
AntibodiesBiologicsSmall Molecules
About
NovalGen is an innovative immunotherapy company focused on next-generation multi-specific antibody approaches
Funding History
2Total raised: $18.5M
Series A$15MUndisclosedMar 15, 2023
Seed$3.5MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2018
LocationLondon, United Kingdom
StagePhase 1
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile